The K.G. Jebsen BTRC Work Programme
The overall objective of the K.G Jebsen BTRC is to adjust the imbalance between our extensive basic and preclinical activities and the clinic. This will be done by the translation of our most promising research results into the clinic. The K.G.J-BTRC will establish a scientific and clinical research environment that will facilitate phase I clinical trials that may ultimately lead to better patient treatment.
The focus of the K.G Jebsen BTRC is to to translate new important knowledge gained from our core research activities into clinical trials.This involves a complete mapping of the human glioblastoma metabolome with the aim of finding newt targets for therapy. The centre activities also aims at implementing a number of Phase I/II clinical trials including both primary and secondaty brain tumours. In particular, these include the use of novel lentiviral vectors for gene therapy as well as drug repurposing based on in-depth genomic characterization and preclinical validation of various treatment strategies.
The work-programme also involves extensive collaboration with other laboratories world-wide.